Sun Pharmaceutical Industries Limited vs Symbiotec Pharmalab Limited
A side-by-side comparison of Sun Pharmaceutical Industries Limited (SUNPHARMA) and Symbiotec Pharmalab Limited (SYMBIOTEC) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Sun Pharmaceutical Industries Limited leads SUNPHARMA vs SYMBIOTEC on 12 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation40
- Profitability40
- Growth02
- Size & financial health40
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
SUNPHARMA takes 4/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
SUNPHARMA takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
SYMBIOTEC takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
SUNPHARMA takes 4/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company has delivered good profit growth of 38.3% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 33.4%", "Company is almost debt free."]
- − ["Stock is trading at 5.05 times its book value"]
- + []
- − ["The company has delivered a poor sales growth of 6.5% over past five years.", "The company has delivered a poor profit growth of -2.2% over past five years.", "Though the company is reporting repeated profits, it is not paying out dividend"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.